Cited 200 times in
Impact of bone and liver metastases on patients with renal cell carcinoma treated with targeted therapy.
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 라선영 | - |
dc.date.accessioned | 2015-12-28T11:04:54Z | - |
dc.date.available | 2015-12-28T11:04:54Z | - |
dc.date.issued | 2014 | - |
dc.identifier.issn | 0302-2838 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/138652 | - |
dc.description.abstract | BACKGROUND: The skeleton and liver are frequently involved sites of metastasis in patients with metastatic renal cell carcinoma (RCC). OBJECTIVE: To analyze outcomes based on the presence of bone metastases (BMs) and/or liver metastases (LMs) in patients with RCC treated with targeted therapy. DESIGN, SETTING, AND PARTICIPANTS: We conducted a review from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) of 2027 patients with metastatic RCC. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: We analyzed the impact of the site of metastasis on overall survival (OS) and time-to-treatment failure. Statistical analyses were performed using multivariable Cox regression. RESULTS AND LIMITATIONS: The presence of BMs was 34% overall, and when stratified by IMDC risk groups was 27%, 33%, and 43% in the favorable-, intermediate-, and poor-risk groups, respectively (p<0.001). The presence of LMs was 19% overall and higher in the poor-risk patients (23%) compared with the favorable- or intermediate-risk groups (17%) (p=0.003). When patients were classified into four groups based on the presence of BMs and/or LMs, the hazard ratio, adjusted for IMDC risk factors, was 1.4 (95% confidence interval [CI], 1.22-1.62) for BMs, 1.42 (95% CI, 1.17-1.73) for LMs, and 1.82 (95% CI, 1.47-2.26) for both BMs and LMs compared with other metastatic sites (p<0.0001). The prediction model performance for OS was significantly improved when BMs and LMs were added to the IMDC prognostic model (likelihood ratio test p<0.0001). Data in this analysis were collected retrospectively. CONCLUSIONS: The presence of BMs and LMs in patients treated with targeted agents has a negative impact on survival. Patients with BMs and/or LMs may benefit from earlier inclusion on clinical trials of novel agents or combination-based therapies. | - |
dc.description.statementOfResponsibility | open | - |
dc.format.extent | 577~584 | - |
dc.relation.isPartOf | EUROPEAN UROLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Bone Neoplasms/secondary* | - |
dc.subject.MESH | Carcinoma, Renal Cell/drug therapy* | - |
dc.subject.MESH | Carcinoma, Renal Cell/secondary* | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Kidney Neoplasms/drug therapy* | - |
dc.subject.MESH | Kidney Neoplasms/pathology* | - |
dc.subject.MESH | Liver Neoplasms/secondary* | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Molecular Targeted Therapy | - |
dc.subject.MESH | Retrospective Studies | - |
dc.title | Impact of bone and liver metastases on patients with renal cell carcinoma treated with targeted therapy. | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학) | - |
dc.contributor.googleauthor | Rana R. McKay | - |
dc.contributor.googleauthor | Nils Kroeger | - |
dc.contributor.googleauthor | Wanling Xie | - |
dc.contributor.googleauthor | Jae Lyun Lee | - |
dc.contributor.googleauthor | Jennifer J. Knox | - |
dc.contributor.googleauthor | Georg A. Bjarnason | - |
dc.contributor.googleauthor | Mary J. MacKenzie | - |
dc.contributor.googleauthor | Lori Wood | - |
dc.contributor.googleauthor | Sandy Srinivas | - |
dc.contributor.googleauthor | Ulka N. Vaishampayan | - |
dc.contributor.googleauthor | Sun Young Rha | - |
dc.contributor.googleauthor | Sumanta K. Pal | - |
dc.contributor.googleauthor | Frede Donskov | - |
dc.contributor.googleauthor | Srinivas K. Tantravahi | - |
dc.contributor.googleauthor | Brian I. Rini | - |
dc.contributor.googleauthor | Daniel Y. C. Heng | - |
dc.contributor.googleauthor | Toni K. Choueiri | - |
dc.identifier.doi | 10.1016/j.eururo.2013.08.012 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A01316 | - |
dc.relation.journalcode | J00854 | - |
dc.identifier.eissn | 1873-7560 | - |
dc.identifier.pmid | 23962746 | - |
dc.subject.keyword | Bone metastases | - |
dc.subject.keyword | Liver metastases | - |
dc.subject.keyword | Outcome | - |
dc.subject.keyword | Renal cell carcinoma | - |
dc.subject.keyword | VEGF therapy | - |
dc.subject.keyword | mTOR inhibitors | - |
dc.contributor.alternativeName | Rha, Sun Young | - |
dc.contributor.affiliatedAuthor | Rha, Sun Young | - |
dc.citation.volume | 65 | - |
dc.citation.number | 3 | - |
dc.citation.startPage | 577 | - |
dc.citation.endPage | 584 | - |
dc.identifier.bibliographicCitation | EUROPEAN UROLOGY, Vol.65(3) : 577-584, 2014 | - |
dc.identifier.rimsid | 38468 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.